Abstract
Failure of conventional as well as target-based therapy against the advanced metastatic cancers is a significant clinical problem. While some cancers, such as pancreatic cancer, respond poorly to any kind of therapies, tumor relapse is often observed in many other cancer types after initial therapeutic response. Hence, significant research is being conducted to understand the mechanisms underlying therapeutic refractoriness of cancer. During the past decade, cancer stem cell (CSC) hypothesis has gained significant experimental and clinical support, and CSCs have emerged as potentially useful pharmacologic targets. MicroRNAs (miRNAs) are a group of small (~18–25 nucleotides) non-protein encoding RNAs that are now established as important regulators of gene expression. They can function as tumor promoters (oncomirs) or suppressors (anti-oncomirs) and thus hold profound implications for cancer therapy. Recent studies have identified several miRNAs to be differentially expressed in CSCs and established their role in targeting genes and pathways supporting cancer stemness properties. Here, we discuss these findings and review recent advances in miRNA-based strategies to exploit therapeutic potential of miRNAs in cancer treatment.
Keywords: Cancer stem cells, cellular mechanisms, MicroRNAs, pancreatic cancer, stemness, therapeutics.
Current Drug Targets
Title:Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Volume: 14 Issue: 10
Author(s): Arun Bhardwaj, Sumit Arora, Vijay K. Prajapati, Seema Singh and Ajay P. Singh
Affiliation:
Keywords: Cancer stem cells, cellular mechanisms, MicroRNAs, pancreatic cancer, stemness, therapeutics.
Abstract: Failure of conventional as well as target-based therapy against the advanced metastatic cancers is a significant clinical problem. While some cancers, such as pancreatic cancer, respond poorly to any kind of therapies, tumor relapse is often observed in many other cancer types after initial therapeutic response. Hence, significant research is being conducted to understand the mechanisms underlying therapeutic refractoriness of cancer. During the past decade, cancer stem cell (CSC) hypothesis has gained significant experimental and clinical support, and CSCs have emerged as potentially useful pharmacologic targets. MicroRNAs (miRNAs) are a group of small (~18–25 nucleotides) non-protein encoding RNAs that are now established as important regulators of gene expression. They can function as tumor promoters (oncomirs) or suppressors (anti-oncomirs) and thus hold profound implications for cancer therapy. Recent studies have identified several miRNAs to be differentially expressed in CSCs and established their role in targeting genes and pathways supporting cancer stemness properties. Here, we discuss these findings and review recent advances in miRNA-based strategies to exploit therapeutic potential of miRNAs in cancer treatment.
Export Options
About this article
Cite this article as:
Bhardwaj Arun, Arora Sumit, Prajapati K. Vijay, Singh Seema and Singh P. Ajay, Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990190
DOI https://dx.doi.org/10.2174/13894501113149990190 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Proteomics in Computer-Aided Drug Design
Current Computer-Aided Drug Design VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Meet Our Editorial Board Member:
Current Medicinal Chemistry